Depression
Research spans established dissociative treatment and experimental classic-psychedelic approaches. The evidence and experience differ substantially by medicine.
Sometimes the medicine is the starting point. Sometimes it is grief, pain, trauma, habit, disconnection, or the hope that life could feel different.
This map shows associations and research questions—not treatment recommendations.A medicine appears here because it is part of current research, established clinical practice in a specific context, or sustained public interest. That does not mean it is approved for the condition—or a good fit for every person.
Research spans established dissociative treatment and experimental classic-psychedelic approaches. The evidence and experience differ substantially by medicine.
Studies often focus on anxiety linked to depression, serious illness, or existential distress rather than treating every kind of anxiety as one category.
The most developed psychedelic-adjacent research centers on MDMA-assisted therapy, where the medicine and structured therapeutic process are studied together.
Small and early studies have explored whether entactogenic effects may support work with social fear in specific populations.
Ketamine is used clinically in some pain settings, while protocols, evidence quality, access, and suitability vary by pain condition.
Psilocybin and LSD have both been studied alongside structured psychological support, with different eras and strengths of evidence.
Ibogaine attracts significant interest and personal testimony, but evidence remains preliminary and cardiac risk makes this a particularly high-stakes area.
Diagnosis labels are only one layer. Intent, expectations, culture, support, medications, physical health, previous experiences, and what happens afterward can matter just as much to the shape of an experience.